Should I buy or sell Certara stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares. View CERT analyst ratings or view top-rated stocks .

What is Certara's stock price target for 2024?

10 equities research analysts have issued 12-month price objectives for Certara's stock. Their CERT share price targets range from $16.00 to $24.00. On average, they expect the company's stock price to reach $19.38 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View analysts price targets for CERT or view top-rated stocks among Wall Street analysts .

How have CERT shares performed in 2023?

Certara's stock was trading at $16.07 at the beginning of 2023. Since then, CERT stock has increased by 1.7% and is now trading at $16.34. View the best growth stocks for 2023 here .

Are investors shorting Certara?

Certara saw a decline in short interest in November. As of November 15th, there was short interest totaling 4,690,000 shares, a decline of 11.0% from the October 31st total of 5,270,000 shares. Based on an average trading volume of 677,600 shares, the short-interest ratio is currently 6.9 days. Currently, 4.3% of the shares of the company are sold short. View Certara's Short Interest .

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our CERT earnings forecast .

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) released its earnings results on Wednesday, November, 8th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. The company earned $85.58 million during the quarter, compared to analysts' expectations of $85.96 million. Certara had a negative net margin of 9.56% and a positive trailing twelve-month return on equity of 5.38%.

What ETFs hold Certara's stock?

ETFs with the largest weight of Certara (NASDAQ:CERT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH) , Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) , Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) , Motley Fool Small-Cap Growth ETF (TMFS) , Janus Henderson US Sustainable Equity ETF (SSPX) , MFAM Small-Cap Growth ETF (MFMS) , BlackRock Future Innovators ETF (BFTR) and iShares U.S. Healthcare Providers ETF (IHF) .

What guidance has Certara issued on next quarter's earnings?

Certara updated its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $0.44-0.48 for the period, compared to the consensus earnings per share estimate of $0.45. The company issued revenue guidance of $345-360 million, compared to the consensus revenue estimate of $353.75 million.

When did Certara IPO?

(CERT) raised $500 million in an IPO on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

Who are Certara's major shareholders?

Certara's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.75%), William Blair Investment Management LLC (4.48%), Clearbridge Investments LLC (2.58%), JPMorgan Chase & Co. (2.44%), Riverbridge Partners LLC (1.65%) and Massachusetts Financial Services Co. MA (1.32%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner , Eran Broshy, James E Cashman III , Jieun W Choe , Justin Edge , Leif E Pedersen, Mason P Slaine , Matthew M Walsh, Michael Andrew Schemick , Patrick F Smith , Richard M Traynor , Robert Aspbury , Stephen M Mclean and William F Feehery . View institutional ownership trends .

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Certara (CERT) Stock Price, News & Analysis

$16.37

-0.06 (-0.37%)

(As of 04:23 PM ET)

Compare

Today's Range: $16.04
▼
$16.54
50-Day Range: $12.12
▼
$16.43
52-Week Range: $11.81
▼
$24.96

Volume: 578,792 shs
Average Volume: 1.00 million shs
Market Capitalization: $2.62 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.38

Certara MarketRank™ Stock Analysis

Analyst Rating: Hold
2.30 Rating Score
Upside/Downside: 18.6% Upside
$19.38 Price Target
Short Interest: Healthy
4.30% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.81
Based on 13 Articles This Week
Insider Trading: Selling Shares
$747,870 Sold Last Quarter
Proj. Earnings Growth: 3.03%
From $0.33 to $0.34 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

308th out of 944 stocks

Prepackaged Software Industry

64th out of 189 stocks

2.2

Analyst's Opinion

Consensus Rating
Certara has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.38, Certara has a forecasted upside of 18.6% from its current price of $16.34.
Amount of Analyst Coverage
Certara has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.30% of the float of Certara has been sold short.
Short Interest Ratio / Days to Cover
Certara has a short interest ratio ("days to cover") of 6.9.
Change versus previous month
Short interest in Certara has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Certara does not currently pay a dividend.
Dividend Growth
Certara does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Certara has received a 63.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Management consulting for the pharmaceutical industry", "Drug discovery software", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Certara is -0.73.

3.8

News and Social Media Coverage

News Sentiment
Certara has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Certara this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for CERT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
2 people have added Certara to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Certara insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $747,870.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of Certara is held by insiders.
Percentage Held by Institutions
67.26% of the stock of Certara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Certara are expected to grow by 3.03% in the coming year, from $0.33 to $0.34 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Certara is -77.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Certara is -77.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Certara has a PEG Ratio of 1.27. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Certara has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Certara Stock (NASDAQ:CERT)

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CERT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CERT Stock News Headlines

December 10, 2023 | msn.com

KeyBanc sees opportunity in tech-enabled drug discovery stocks

December 9, 2023 | americanbankingnews.com

Certara (NASDAQ:CERT) Receives New Coverage from Analysts at UBS Group

December 11, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

December 9, 2023 | americanbankingnews.com

Analysts Issue Forecasts for Certara, Inc.'s FY2023 Earnings (NASDAQ:CERT)

December 7, 2023 | msn.com

UBS Initiates Coverage of Certara (CERT) with Neutral Recommendation

December 6, 2023 | americanbankingnews.com

Certara (NASDAQ:CERT) Now Covered by KeyCorp

November 22, 2023 | finanznachrichten.de

Certara introduces Simcyp Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

November 21, 2023 | finance.yahoo.com

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

December 11, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 10, 2023 | finance.yahoo.com

Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

Q3 2023 Certara Inc Earnings Call

November 9, 2023 | seekingalpha.com

Certara, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 8, 2023 | finance.yahoo.com

Certara, Inc. (CERT) Q3 Earnings Meet Estimates

November 8, 2023 | msn.com

Certara Non-GAAP EPS of $0.11, revenue of $85.6M

November 8, 2023 | finance.yahoo.com

Certara Reports Third Quarter 2023 Financial Results

October 20, 2023 | finance.yahoo.com

Are Options Traders Betting on a Big Move in Certara (CERT) Stock?

October 17, 2023 | finance.yahoo.com

Are Certara, Inc.'s (NASDAQ:CERT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

October 17, 2023 | seekingalpha.com

Circling Back On Certara

October 12, 2023 | msn.com

Stephens & Co. Reiterates Certara (CERT) Overweight Recommendation

October 11, 2023 | finance.yahoo.com

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

October 1, 2023 | finance.yahoo.com

Are Investors Undervaluing Certara, Inc. (NASDAQ:CERT) By 23%?

September 21, 2023 | markets.businessinsider.com

Robert W. Baird Reaffirms Their Hold Rating on Certara (CERT)

September 19, 2023 | finance.yahoo.com

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

September 15, 2023 | barrons.com

Certara Inc.

September 14, 2023 | finance.yahoo.com

What Is Certara, Inc.'s (NASDAQ:CERT) Share Price Doing?

September 13, 2023 | it.tmcnet.com

Simulation Software Market worth $33.5 billion by 2028 - Exclusive Report by MarketsandMarkets™

September 13, 2023 | finance.yahoo.com

Insider Sell: Leif Pedersen Sells 51,224 Shares of Certara Inc (CERT)

See More Headlines

Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Prepackaged software
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CERT
CUSIP: N/A
CIK: 1827090
Web: www.certara.com
Phone: 609-716-7900
Fax: N/A
Employees: 1,204
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.38
High Stock Price Target: $24.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +18.4%
Consensus Rating: Hold
Rating Score (0-4): 2.30
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 49.58
P/E Growth: 1.27
Net Income: $14.73 million
Net Margins: -9.56%
Pretax Margin: -11.06%
Return on Equity: 5.38%
Return on Assets: 3.72%

Debt

Debt-to-Equity Ratio: 0.27
Current Ratio: 3.51
Quick Ratio: 3.51

Sales & Book Value

Annual Sales: $352.96 million
Price / Sales: 7.41
Cash Flow: $0.66 per share
Price / Cash Flow: 24.85
Book Value: $6.76 per share
Price / Book: 2.42

Miscellaneous

Outstanding Shares: 159,845,000
Free Float: 155,689,000
Market Cap: $2.62 billion
Optionable: Not Optionable
Beta: 1.57

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. William F. Feehery Ph.D. (Age 52)
CEO & Director
Comp: $1.35M
Mr. Leif E. Pedersen (Age 58)
President & Chief Commercial Officer
Comp: $625.53k
Dr. Robert P. Aspbury Ph.D. (Age 51)
President of Certara Scientific Software
Comp: $518.09k
Dr. Patrick F. Smith Pharm.D. (Age 52)
President of Drug Development Solutions
Comp: $621.58k
Mr. John E. Gallagher III (Age 50)
Chief Financial Officer
Mr. Max Kanevsky
Chief Technology Officer
Prof. Amin Rostami PharmD
Ph.D., FCP, Chief Scientific Officer
Mr. Richard M. Traynor (Age 51)
Senior VP, General Counsel & Secretary
Mr. Ron DiSantis
Senior Vice President of Corporate Development
Ms. Sheila Rocchio MBA
Chief Marketing Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERT Stock Analysis - Frequently Asked Questions

Should I buy or sell Certara stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares.
View CERT analyst ratings or view top-rated stocks.
What is Certara's stock price target for 2024?: 10 equities research analysts have issued 12-month price objectives for Certara's stock. Their CERT share price targets range from $16.00 to $24.00. On average, they expect the company's stock price to reach $19.38 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price.
View analysts price targets for CERT or view top-rated stocks among Wall Street analysts.
How have CERT shares performed in 2023?: Certara's stock was trading at $16.07 at the beginning of 2023. Since then, CERT stock has increased by 1.7% and is now trading at $16.34.
View the best growth stocks for 2023 here.
Are investors shorting Certara?: Certara saw a decline in short interest in November. As of November 15th, there was short interest totaling 4,690,000 shares, a decline of 11.0% from the October 31st total of 5,270,000 shares. Based on an average trading volume of 677,600 shares, the short-interest ratio is currently 6.9 days. Currently, 4.3% of the shares of the company are sold short.
View Certara's Short Interest.
When is Certara's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our CERT earnings forecast.
How were Certara's earnings last quarter?: Certara, Inc. (NASDAQ:CERT) released its earnings results on Wednesday, November, 8th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. The company earned $85.58 million during the quarter, compared to analysts' expectations of $85.96 million. Certara had a negative net margin of 9.56% and a positive trailing twelve-month return on equity of 5.38%.

What ETFs hold Certara's stock?: ETFs with the largest weight of Certara (NASDAQ:CERT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG), Motley Fool Small-Cap Growth ETF (TMFS), Janus Henderson US Sustainable Equity ETF (SSPX), MFAM Small-Cap Growth ETF (MFMS), BlackRock Future Innovators ETF (BFTR) and iShares U.S. Healthcare Providers ETF (IHF).
What guidance has Certara issued on next quarter's earnings?: Certara updated its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $0.44-0.48 for the period, compared to the consensus earnings per share estimate of $0.45. The company issued revenue guidance of $345-360 million, compared to the consensus revenue estimate of $353.75 million.
When did Certara IPO?: (CERT) raised $500 million in an IPO on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.
Who are Certara's major shareholders?: Certara's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.75%), William Blair Investment Management LLC (4.48%), Clearbridge Investments LLC (2.58%), JPMorgan Chase & Co. (2.44%), Riverbridge Partners LLC (1.65%) and Massachusetts Financial Services Co. MA (1.32%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, Eran Broshy, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends.
How do I buy shares of Certara?: Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CERT) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial